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Abstract 
Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD) have 
negative impact in the course of disease. Comorbidities are frequent and play an important role 
in COPD. COPD Assessment Test (CAT) is responsive to interventions, such as AECOPD. The 
main goal of this study is to determine the role of comorbidities and CAT responsiveness in 
AECOPD. 
This study is conducted in emergency department (ED) where a CAT was performed. 
Inclusion criteria: (1) > 40 years; (2) FEV1 < 80% predicted and FEV1/FCV < 0,70 (3) AECOPD 
as main diagnosis. Exclusion criteria: (1) other condition than COPD as main diagnosis; (2) 
unknown or inaccessible FEV1 and/or FEV1/FVC; (3) inability to answer CAT. Demographic and 
clinical data such as comorbidities were collected. Participants were prospectively followed up 
for 30 days. Hospitalization and the length of hospitalization, readmissions, rehospitalizations 
and fatality were recorded. Thirty days after discharge, a new CAT was performed.  
The most common comorbidities were hypertension (64,4%), heart failure (49,6%) and 
dyslipidemia (47%). 63,5% were hospitalized. The length of hospitalization was 11,5±11,1 days. 
30,4% were readmitted. The 30-day fatality was 3,5%. CAT recovery was 3,6±3,7 between ED 
admission and 30 days after discharge. Hospitalized, non-readmitted and non-rehospitalized 
patients had greater CAT recovery. Underweight patients and obese patients had a worse CAT 
recovery. Overweight patients had greater CAT recovery. Gastroesophageal reflux disease 
(GERD) was associated with ED readmission for AECOPD (OR 2.92; IC95% (1,14-7,47)) and 
with rehospitalization for AECOPD (OR 3.31; IC95% (1,06-10,38)). Cerebrovascular disease 
was also associated with rehospitalization for AECOPD (OR 5.23; IC 95% (1,09-24,95)) and 30-
day fatality (p=0,024).  
The prevalence of comorbidities is high. AECOPD is associated with a high rate of 
hospitalization and length of hospitalization, ED readmissions and rehospitalizations at 30 days. 
GERD and cerebrovascular disease increase ED readmission and rehospitalization rates; 
cerebrovascular disease worsens 30-day fatality.  CAT score is responsive to recovery and 
sensitive for AECOPD relapses and other clinical entities.  Body mass index is relevant in CAT 
score recovery. 
  
Keywords: Chronic obstructive pulmonary disease; COPD; Acute exacerbation of COPD; 
comorbidities; COPD Assessment Test; CAT. 
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Resumo 
As exacerbações agudas da doença obstrutiva crónica (EADPOC) têm impacto negativo 
no curso da doença. As comorbilidades são frequentes e desempenham um papel importante 
na DPOC. O COPD Assessment Test (CAT) é responsivo a intervenções, como à EADPOC. O 
objectivo principal deste estudo é determinar o papel das comorbilidades e a responsividade do 
CAT na EADPOC. 
O estudo foi realizado no serviço de urgência onde o CAT foi realizado aos 
participantes. Os critérios de inclusão foram: (1) > 40 anos de idade; (2) FEV1 < 80% valor 
predito e FEV1/FCV < 0,70 (3) EADPOC como diagnostico principal. Os critérios de exclusão 
foram: (1) outras condições além de DPOC como dagnostico principal; (2) FEV1 e/ou FEV1/FVC 
desconhecido ou inacessivel; (3) incapacidade de responder ao CAT. Informação demográfica 
e clínica como as comorbilidades foi registada. Os participantes foram seguidos 
prospectivamente durante 30 dias. Internamento e duração do internamento, readmissões, 
reinternamentos e letalidade foram registados. Trinta dias depois da alta hospitalar, um novo 
CAT foi realizado. 
As comorbilidades mais comuns foram: hipertensão (64,4%), insuficiência cardiaca 
(49,6%) e dislipidemia (47%). 63,5% foram internados. A duração do internamento foi 
11,5±11,1 dias. A fatalidade aos 30 dias foi 3,5%. A recuperação no CAT foi 3,6±3,7 entre a 
admissão e 30 dias depois da alta hospitalar. Os participantes internados, os que não foram 
readmitidos nem reinternados mostraram uma recuperação mais acentuada no CAT. 
Participantes com baixo indice de massa corporal (IMC) e obesos mostraram pior recuperação. 
Participantes com excesso de peso mostraram melhor recuperação. Doença do refluxo 
gastroesofágico (DRGE) foi associada com as readmissões por EADPOC (OR 2.92; IC95% 
(1,14-7,47)) e com rehospitalizações por EADPOC (OR 3.31; IC95% (1,06-10,38)). Doença 
cerebrovascular também foi assocada a rehospitalizações por EADPOC (OR 5.23; IC 95% 
(1,09-24,95)) e fatalidade aos 30 dias (p=0,024).  
A prevalência de comorbilidades é alta. A AEDPOC é associada a uma alta taxa de 
hospitalizações e duração de internamento, readmissões e rehospitalizações aos 30 dias. A 
DRGE e as doenças cerebrovasculares aumentam as taxas de readmissão e  rehospitalização; 
a doença cerebrovascular piora a letalidade aos 30 dias. O CAT é responsivo à recuperação e 
sensivel para EADPOC recaídas e outras entidades clínicas. O IMC é relevante na 
recuperação do CAT. 
Palavras-chave: Doença pulmonar obstrutiva crónica; DPOC; exacerbação aguda da 
DPOC; comorbilidades; COPD Assessment Test; CAT. 
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Introduction  
Chronic Obstructive Pulmonary Disease (COPD) is defined as a common preventable 
and treatable disease that is characterized by persistent airflow limitation that is usually 
progressive [1]. 
In Europe, the prevalence of COPD is between 2% and 10%  [2]. In Portugal a 
prevalence of 14,2% was reported [3]. COPD is the fourth leading cause of death worldwide, 
and it is estimated to become the third leading cause of death by 2020 [4]. It is estimated that by 
2020, COPD will be the fifth most important cause of burden of disease and chronic disability 
[5]. In Europe, COPD is responsible for 56% of the costs of respiratory diseases and COPD 
exacerbations is the major contributor for the total COPD burden on the health care system [1]. 
Acute exacerbations of COPD (AECOPD) are major events with negative impact on the 
course of the disease [1].  They are associated with transient decreases in lung function that 
can take several weeks to recover [6]. Moreover, frequent AECOPD are associated with more 
rapid decline of forced expiratory volume in 1 second (FEV1) [7].  AECOPD also negatively 
affect the patients’ quality of life [8]. The overall exercise tolerance, physical activity [9] and the 
physiological wellbeing [10] are also reduced during an AECOPD. Finally, AECOPD are 
associated with significant mortality, especially those requiring hospitalization [11].  
Several risk factors for frequent AECOPD were identified, namely increased age, 
severity of FEV1 impairment, frequent past exacerbations, persistent symptoms of chronic 
bronchitis and comorbid conditions, mainly cardiovascular disease [12]. 
Comorbidities are frequent among COPD patients [1]. They play an important role in the 
history of the disease. Firstly, they can share similar pathophysiological mechanisms with 
COPD. Secondly, their impact on health status, healthcare utilization and all-cause hospital 
admissions is significant. Thirdly, mortality due to comorbidities can occur earlier than 
respiratory causes. Finally, understanding the clusters of comorbidities can have diagnostic, 
therapeutic and prognostic implications [2]. 
Classifying COPD only based on FEV1 % of predicted is no longer adequate. Nowadays, 
COPD classification and management are both based on spirometric criteria and patients’  
health-related quality of life. COPD health status measurements, such as the St. George 
Respiratory Questionnaire and Chronic Respiratory Questionnaire provide this additional 
information but their complexity made them impractical in for use in clinical routine. Recent 
guidelines recommend either the modified British Medical Research Council (mMRC) dyspnoea 
scale or the COPD assessment test (CAT). COPD assessment test (CAT) is a simple 
instrument that provides information not only about the symptoms but also about the impact of 
COPD on wellbeing [1]. 
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Several studies support the reliability and validity of the CAT and its responsiveness to 
interventions, such as pulmonary rehabilitation [13] [14] [15] and exacerbation recovery on 
treatment [16] [17] [14] [18] [19]. However, its validity and responsiveness need to be assessed 
in specific patient populations [20]. 
The present study had three main goals: (1) to determine the role of comorbidities on 
AECOPD, defining their importance on length of hospitalization and short-term emergency 
department readmissions, rehospitalizations and mortality; (2) to define the CAT score 
responsiveness to AECOPD recovery, to quantify the CAT score improvement at 30 days and 
to determine the role of comorbidities in this score recovery; (3) to analyze the differences in 
CAT score recovery 30 days after an AECOPD among readmitted or rehospitalized and non-
readmitted or non-rehospitalized patients for all causes and for AECOPD. 
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Material and methods 
 Study design and setting 
The present study is a longitudinal and observational study conducted from 1.September 
2014 to 31. January 2015 in the emergency department (ED) of Hospital de Santo António – 
Centro Hospitalar do Porto, a central hospital in Porto, Portugal. The study was approved by the 
Ethics Committee of Centro Hospitalar do Porto. The patients participated voluntarily and 
written informed consent forms were obtained. 
 
Patients 
The inclusion criteria were: (1) age above 40 years; (2) Forced expiratory volume in 1 
second (FEV1) < 80% predicted and Tiffeneau index (FEV1/FCV) < 0,70 (3) ED admission with 
AECOPD as main diagnosis. 
The exclusion criteria were: (1) other condition than COPD as main diagnosis; (2) unknown or 
inaccessible FEV1 and/or FEV1/FVC; (3) inability to answer CAT questionnaire (e.g. severe 
dementia, severe cognitive disability). 
 
Definitions 
A AECOPD was defined as an acute change of baseline symptoms (dyspnea, cough, 
and/or sputum production) that is beyond normal day-to-day variation [1]. 
CAT is a questionnaire that measures the impact of COPD on patient´s health status. It 
evaluates the following 8 items: cough, dyspnea, sputum production, chest tightness, impair-
ment in daily activities, confidence, quality of sleep and energy. Each item is evaluated from 0 to 
5, an higher score meaning greater severity. [21]. 
Comorbidities were considered concurrent diseases and chronic medical conditions that 
may affect COPD patients [22]. 
 
Data collection  
Participants were recruited at the ED admission and prospectively followed up for 30 
days. All data was entered in a form specifically designed for the study.  
At admission, symptoms were evaluated with CAT. Illiterate and other patients with 
difficulties in self-administering the CAT were questioned orally.  Patients’ demographic and 
clinical data were collected retrospectively based on clinical files and completed with an 
interview during ED admission. The demographic data included sex, age, education, home, 
professional and marital status. The clinical data included COPD-related characteristics and a 
comorbidity check-list. Among COPD-related characteristics, smoker status (non-smoker, 
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smoker, ex-smoker) and pack-year, FEV1 and FEV1/FVC, Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) classification of severity of airflow limitation and GOLD 
combined classification, previous year exacerbations and hospitalizations and COPD 
management context (primary care or hospital care) were registered. Pharmacotherapy and 
other treatments (oxygen therapy, non-invasive ventilation, pulmonary rehabilitation, flu and 
pneumococcal vaccination) administered in the previous 12 months were also recorded. 
In the follow-up period, the need for hospitalization and the length of hospitalization were 
recorded. Thirty days after the hospital discharge, a new CAT was performed by telephone 
interview. Fatality, ED readmissions, new hospitalizations (rehospitalizations) and their 
respective causes were obtained based on electronic health records and completed with phone 
interview. 
 
Statistics 
Categorical variables were described as number of cases and percentages and 
compared using the chi-square or Fisher’s exact test. Continuous variables as median and 
standard deviation and compared using the t-test, Mann-Whitney U test or Kruskal-Wallis test, 
as appropriated.   The Spearman’s test was used to compare the continuous variables: number 
of comorbidities, length of hospitalization, CAT at admission, CAT recovery. Additionally, the 
associations between comorbidities and the study outcomes (hospitalization, ED readmission, 
rehospitalization, fatal outcome) were assessed using chi-square or Fisher’s exact test. The 
magnitude of the associations with the study outcomes was assessed using logistic regression 
and presented as odds ratio (OR) and respective 95% confidence intervals (95%CI).  
All p-values were two tailed and statistical significance was defined as p <0.05. 
Statistical analyses were performed using the software STATA® 13.0 (StataCorp, USA). 
 
 
  
 Comorbidities and COPD Assessment Test (CAT) responsiveness in Acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD) 
 
21 
Results 
A total of 115 patients were enrolled in the study. Table 1 describes the demographic 
and clinical characteristics of the patients. Mean age was 71,9±11,7 and 77,4 % were men. 64,4 
% patients had at least four years of education and 17,4 % were illiterate. The majority lived 
with one or more family members (76,5%), 20,9% lived alone and only 3 patients were 
institutionalized; 84,3% had retired, 63,5% were married and 17,4% were widowed.  
A proportion of 61,7% were former smokers and mean packs/year was 55,8±39,0. Mean 
FEV1 was 49,2±15,2% predicted and mean FEV1/FVC was 53,7±10,9. The majority of the 
patients had either moderate (46,1%) or severe (40%) airflow limitation. The rest of the patients 
had very severe airway obstruction (13,9%). None had a mild (GOLD 1) airflow limitation. GOLD 
COPD combined assessment showed that the majority belong to groups with “more symptoms” 
(group D with 34,8% and group B with 33,9%). Group C accounts for 20,9 % and group A for 
10,4% of the patients. In the previous year, 61,7% (N=71) admitted in the ED for AECOPD and 
39 of these were hospitalized. 
The most common comorbidities were hypertension (64,4%), heart failure (49,6%) and 
dyslipidemia (47%). Also common are anxiety (35,7%), overweight (33%), gastroesophageal 
reflux disease (GERD) (32,2%), bronchiectasis (27%), type 2 diabetes mellitus (24,4%), 
arrhythmias (20%), ischemic heart disease (19,1%) and depression (19,1%). Of the 23 patients 
with cardiac arrhythmia, 21 had atrial fibrillation (AF). Of the 10 patients with extrapulmonary 
neoplasia, five had colorectal, two had bladder, two had prostate and one had laryngeal cancer. 
The mean body mass index (BMI) was 25,0±5,1 kg/m
2
. A proportion of 46,1% had normal BMI 
and only 7 patients were underweight. Overall, 19,1% (N=22) had community-acquired 
pneumonia (CAP) requiring ED admission in the previous 12 months. Of these, 17 were 
hospitalized due to CAP in the same period. 
Figure 1 shows the burden of comorbidities.  
 
 
Figure 1: Burden of comorbidities 
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Table 1: Demographic and clinical characteristics 
 Demographic Characteristics  
 Male 77,4 (89) 
 Age 71,9 ± 11,7 
 Education (years)  
 0 17,4 (20) 
 ≤4 64,4 (74) 
 >4 ≤6 0,9 (1) 
 >6 ≤9 13% (15) 
 >9 ≤12 4,4 (5) 
 Home Status  
 Alone 20,9 (24) 
 Family 76,5 (88) 
 Institution 2,6 (3) 
 Profissional Status  
 Employed 6,1 (7) 
 Unemployed 9,6 (11) 
 Retired 84,3 (97) 
 Marital Status  
 Single 7,8 (9) 
 Married 63,5 (73) 
 Divorced 11,3 (13) 
 Widowed 17,4 (20) 
 Clinical Characteristics  
 COPD related characteristics  
 Smoke Status  
 Non-smoker 13 (15) 
 Smoker 25,2 (29) 
 Ex-smoker 61,7 (71) 
 Pack-year 55,8 ± 39,0 
 FEV1 49,2 ± 15,2 
 FEV1/FVC 53,7 ± 10,9 
 GOLD Classification of Severity of Airflow Limitation  
 1 0 (0) 
 2 46,1 (53) 
 3 40,0 (46) 
 4 13,9 (16) 
 GOLD combined COPD assessment  
 A 10,4 (12) 
 B 33,9 (39) 
 C 20,9 (24) 
 D 34,8 (40) 
 AECOPD requiring ED admission in the last 12 months  61,7 (71) 
 With hospitalization 33,9 (39) 
 COPD management  
 Primary health care 13,9 (16) 
 Hospital care 86,1 (99) 
 Comorbidities  
 Respiratory  
 Community-acquired pneumonia in the last 12 months  19,1 (22) 
 With hospitalization 14,7 (17) 
 Asthma 9,6 (11) 
 Obstructive Sleep Apnea 8,7 (10) 
 Bronchiectasis 27,0 (31) 
 Risk exposure 19,1 (22) 
 Cardiovascular  
 Heart Failure 49,6 (57) 
 Previous acute myocardial infarct 7,0 (8) 
 Ischemic heart disease 19,1 (22) 
 Arrhytmias 20,0 (23) 
 Hypertension 64,4 (74) 
 Peripheric artery disease 3,5 (4) 
 Previous venous thrombosis/Pulmonary 
thromboembolism 
2,6 (3) 
 Previous stroke 7,0 (8) 
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 Metabolic  
 Body mass index (kg/m
2
) 25,0 ± 5,2 
 Underweight 6,1 (7) 
 Normal 46,1 (53) 
 Overweight 33,0 (38) 
 Obesity 14,8 (17) 
 Type 2 Diabetes Mellitus  24,4 (28) 
 Dyslipidemia 47,0 (54) 
 Ostheoporosis 6,1 (7) 
 Psychiatric  
 Anxiety 35,7 (41) 
 Depression 19,1 (22) 
 Neoplasic  
 Pulmonary 2,6 (3) 
 Extra-pulmonary 8,7 (10) 
 Other  
 Chronic Kidney Disease 13,0 (15) 
 Chronic Kidney Disease Stages   
 1 13,3 (2) 
 2 6,7 (1) 
 3 46,7 (7) 
 4 26,7 (4) 
 5 6,7 (1) 
 Gastroesophageal reflux disease 32,2 (37) 
 Gastritis 4,4 (5) 
 Peptic Ulcer 0,9 (1) 
 Chronic Hepatic Disease 1,7 (2) 
 Benign Prostatate Hypertrophy 14,6 (13) 
 Previous 12 months therapy  
 Anticholinergic  
 Short-acting 16,5 (19) 
 Long-acting 54,8 (63) 
 B2-agonists  
 Short-acting 18,3 (21) 
 Long-acting 79,1 (91) 
 Methylxanthines 23,5 (27) 
 Inhaled corticosteroids 63,5 (73) 
 Systemic costicosteroids 5,2 (6) 
 B-blocker 33,9 (39) 
 Angiotension-convertig enzyme inhibitors  36,5 (42) 
 Angiotensin II receptor blockers  7,9 (9) 
 Calcium channel blocker 13,9 (16) 
 Diuretic 55,7 (64) 
 Statin 38,3 (44) 
 Antiplatelet aggregation agents  33,0 (38) 
 Anticoagulant agents  10,4 (12) 
 Oral antidiabetic agents  20,0 (23) 
 Insulin 6,1 (7) 
 Proton pump inhibitors 34,8 (40) 
 Benzodiazepines 28,7 (33) 
 Antidepressants 13,0 (15) 
 Oxygen therapy 25,2 (29) 
 Non-invasive ventilation  
 CPAP 4,3 (5) 
 BPAP 6,1 (7) 
 Pulmonary reabilitation 10,4 (12) 
 Flu vaccionation 77,4 (89) 
 Pneumcoccal vaccination 45,2 (52) 
 Quantitative variab les are presented as mean ± standard deviation. Discrete variab les 
are presented as percentage (cases). GOLD - Global Initiative for Chronic Obstructive 
Lung Disease;  FEV1 - forced expiratory volume in 1 second;  FEV1/FVC - forced 
expiratory volume in 1 second/forced vital capacity;  AECOPD= acute exacerbation od 
chronic obstructive pulmonary disease; CPAP - Continuous positive airway pressure ; 
BPAP - Bilevel positive airway pressure 
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Hospitalization, 30-day ED readmissions, rehospitalizations and fatality 
Almost two thirds (63,5%) of AECOPD patients were hospitalized. The mean length of 
hospitalization was 11,5±11,1 days. Overall, 30,4% (N=35) were readmitted in the ED due to 
any cause, 22 of these were hospitalized. Concerning ED readmission cause, 23 were 
readmitted for AECOPD, nine for acute heart failure and three for infection.  The 30-day fatality 
related to any cause was 3,5% (N=4). All deaths occurred during a subsequent hospitalization.  
 
CAT at ED admission, after 30 days and recovery 
CAT at ED admission, at 30-days and their difference (CAT recovery) is shown in table 
2. Mean CAT in ED admission was 22,0±6,2 (95% confidence interval(CI)) and at 30 days after 
hospital discharge was 18,4±6,8 (95% CI). CAT decreased between ED admission for AECOPD 
and 30 days after discharge. Mean CAT recovery was 3,6±3,7 (95% CI). Moreover, patients 
whose ED visit determined hospitalization improved 3,9±3,8 CAT points (95% CI), whereas 
patients who were not hospitalized improved 3,1±3,4 (95% CI). 
Among patients that had an ED readmission for any cause, the recovery was less 
pronounced (2,7±2,3, 95% CI) than among patients that had no additional admissions (4,0±4,1; 
95% CI).  CAT score recovery also showed differences between patients rehospitalized for any 
cause (2,3±2,0; 95% CI) and non-rehospitalized (3,9±4,0; 95% CI). Comparing patients who 
had an ED readmission for AECOPD with those who did not, the first group had a less 
pronounced recovery on CAT (2,5±2,2; 95% CI versus 3,9±3,9; 95% CI). The same trend was 
found comparing patients who were rehospitalized for AECOPD and the ones who did not 
(2,6±2,2; 95% CI versus 3,7±3,8; 95% CI). 
 
Table 2: CAT at ED admission, CAT 30 days after hospital discharge and CAT recovery 
 Cases 
CAT 
P-value 
ED admission 
30 days after 
discharge 
Recovery 
      
Sample 111 22,0 ± 6,2 18,4 ± 6,8 3,6 ± 3,7 <0,001 
       
Hospitalization 
Yes 70 22,4 ± 6,6 18,5 ± 7,2 3,9 ± 3,8 <0,001 
No 41 21,3 ± 5,5 18,2 ± 6,2 3,1 ± 3,4 <0,001 
       
ED readmission for any cause 
Yes 34 21,0 ± 5,6 18,2 ± 6,7 2,7 ± 2,3 <0,001 
No 77 22,4 ± 6,4 18,4 ± 6,9 4,0 ± 4,1 <0,001 
       
ED readmission for AECOPD 
Yes 22 19,7 ± 4,8 17,2 ± 5,5 2,5 ± 2,2 <0,001 
No 89 22,6 ± 6,4 18,7 ± 7,1 3,9 ±  3,9 <0,001 
       
Rehospitalization for any cause 
Yes 22 21,4 ± 6,0 19,0 ± 6,6 2,3 ± 2,0 <0,001 
No 89 22,1 ± 6,3 18,2 ± 6,9 3,9 ± 4,0 <0,001 
       
Rehospitalization for AECOPD 
Yes 13 18,8 ± 5,6 16,2 ± 6,3 2,6 ± 2,2 <0,001 
No 98 22,4 ± 6,2 18,7 ± 6,9 3,7 ± 3,8 <0,001 
AECOPD - acute exacerbation of chronic obstructive pulmonary disease; CAT - COPD assessment test 
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Comorbidities and CAT during ED admission and 30-days CAT recovery  
Table 3 shows the relationship between CAT score during ED admission and CAT 
recovery for each comorbidity. No relationship was found between CAT during ED admission 
and each comorbidity. An association between CAT recovery and BMI was found (p=0.003). 
Underweight patients had the worst CAT recovery (1,8±1,2), followed by the obese (2,7±2,4). 
Compared to their overweight counterparts (5,0±3,6), normal BMI patients had a less 
pronounced CAT recovery (3,2±4,1). No relationship was found between CAT recovery and 
other comorbidities. 
CAT during ED admission (Spearman’s Coefficient = 0,10; p = 0,280) and CAT recovery 
(Spearman’s Coefficient 0,16; p = 0,870) were shown to be independent of the number of 
comorbidities . 
 
Comorbidities and hospitalization, 30-day ED readmission and rehospitalization 
and fatality 
Table 4 shows the relationship between comorbidities, hospitalization and its length. No 
comorbidities were positively associated with hospitalization or the length of hospitalization. 
Table 5 shows the relationship between comorbidities and ED readmission, for any 
cause and for AECOPD. Table 6 shows the relationship between comorbidities and 
rehospitalization for any cause and for AECOPD. No single disease was associated either with 
ED readmission or rehospitalization for any cause in the subsequent 30 days. GERD was 
associated with an increased risk of ED readmission for AECOPD at 30 days (OR 2.92; CI95% 
= (1,14-7,47)) as well as with an increased risk of rehospitalization for AECOPD (OR 3.31; 
CI95% = (1,06-10,38)). Previous history of stroke was also associated with higher risk of 
rehospitalization for AECOPD (OR 5.23; CI95% = (1,09-24,95)). 
Table 7 shows the association between comorbidities and fatality. An association 
between previous history of stroke and 30-day fatality was found (p=0.024).  
 
 
Number of comorbidities and hospitalization, 30-days ED readmission and 
rehospitalizations 
Both hospitalization during ED admission (p=0,479) and the length of hospitalization 
(Spearman’s Coefficient = 0,04; p = 0,690) were shown to be independent of the number of 
comorbidities. Also, both ED readmissions (p= 0,522) and rehospitalization (p= 0,891) for any 
cause were shown to be independent of the number of comorbidities. 
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Table 3: Comparison of CAT at ED admission and 30-days CAT recovery and comorbidities 
 CAT at ED admission  CAT recovery 
 Cases Mean 
Standard 
deviation  
P-value 
 
Cases Mean 
Standard 
deviation  
P-value 
Respiratory          
Community-acquired pneumonia in 
the last 12 months 
22 23,0 5,4 0,464  22 3,0 4,2 0,224 
Asthma 11 24,7 4,9 0,076  11 4,1 2,6 0,200 
Obstructive Sleep Apnea 10 19,7 7,6 0,366  10 4,4 4,1 0,425 
Bronchiectasis 31 21,2 6,2 0,379  31 3,5 4,2 0,725 
Cardiovascular          
Heart Failure 57 22,8 5,5 0,199  55 3,5 4,0 0,553 
Previous acute myocardial infarct 8 23,4 7,1 0,485  7 4,3 4,8 0,913 
Ischemic heart disease 22 21,6 5,5 0,581  21 3,6 4,9 0,328 
Arrhytmias 23 22,1 6,2 0,737  22 3,1 5,3 0,125 
Hypertension 74 22,8 5,5 0,157  71 3,8 4,1 0,595 
Peripheric artery disease 4 25,0 6,2 0,423  3 9,0 9,5 0,190 
Previous venous thrombosis/ 
Pulmonary thromboembolism 
3 29,7 6,7 0,061  3 8,0 7,9 0,248 
Previous stroke 8 23,8 6,2 0,458  6 1,5 1,5 0,057 
Metabolic          
Body mass index          
   Underweight 7 23,0 5,7 
0,959 
 6 1,8 1,2 
0,003 
   Normal 53 22,1 6,0  52 3,2 4,1 
   Overweight 38 22,3 6,4  36 5,0 3,6 
   Obesity 17 21,8 7,1  17 2,7 2,4 
Type 2 Diabetes Mellitus  28 22,4 6,2 0,772  28 3,8 3,4 0,537 
Dyslipidemia 54 22,4 5,8 0,728  52 3,7 4,0 0,873 
Ostheoporosis 7 22,0 3,8 0,783  7 3,9 6,6 0,903 
Psychiatric          
Anxiety 41 22,3 5,4 0,944  40 4,1 4,2 0,321 
Depression 22 22,3 5,6 0,926  20 4,7 4,3 0,123 
Neoplasic          
Pulmonary 3 24,7 3,8 0,477  2 3,0 4,2 0,807 
Extra-pulmonary 10 23,7 7,2 0,457  9 4,3 5,3 0,931 
Other          
Chronic Kidney Disease 15 23,1 6,3 0,274  15 3,4 3,7 0,904 
Gastroesophageal reflux disease 37 22,5 5,0 0,871  35 3,8 5,5 0,268 
Gastritis 5 21,6 3,8 0,617  5 5,0 6,8 0,820 
Peptic Ulcer 1 22,0 NA 0,857  1 6,0 NA 0,268 
Chronic Hepatic Disease 2 20,0 1,4 0,410  2 3,0 0,0 0,983 
Benign Prostatate Hypertrophy 13 24,2 4,1 0,170  13 3,1 3,4 0,233 
¶ - logistic-regression analysis; NA – Not applicable; CAT - COPD assessment test 
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Table 4: Comparison of comorbidities between hospitalized and non-hospitalized patients and their 
relationship with the length of hospitalization 
 Hospitalization  Length of hospitalization 
 No Yes  Univariable analysis
¶
 
 
Cases Mean 
Standard 
deviation 
P-value 
 n=42 n=73 P-value OR 95% CI      
Respiratory          
Community-acquired 
pneumonia in the last 
12 months 
7 15 0,611 1,29 0,48-3,48 
 
22 7,73 13,04 0,873 
Asthma 2 9 0,200 2,81 0,58-13,69  11 8,55 7,12 0,199 
Obstructive Sleep 
Apnea 
3 7 0,655 1,38 0,34-5,64 
 
10 5,80 6,43 0,972 
Bronchiectasis 14 17 0,244 0,61 0,26-1,41  31 6,97 11,61 0,474 
Cardiovascular 
Heart Failure 16 41 0,064 2,88 0,96-4,52  57 8,05 9,99 0,175 
Previous acute 
myocardial infarct 
2 6 0,483 1,79 0,34-9,30 
 
8 6,50 7,39 0,804 
Ischemic heart 
disease 
5 17 0,142 2,25 0,76-6,62 
 
22 6,14 6,27 0,768 
Arrhytmias 6 17 0,249 1,82 0,66-5,05  23 8,74 8,73 0,195 
Hypertension 24 50 0,223 1,63 0,74-3,58  74 7,86 9,54 0,112 
Peripheric artery 
disease 
2 2 0,573 0,56 0,08-4,15 
 
4 4,50 5,26 0,625 
Previous venous 
thrombosis/ 
Pulmonary 
thromboembolism 
2 1 0,302 0,28 0,02-3,16 
 
3 3,67 6,35 0,488 
Previous stroke 4 4 0,417 0,55 0,13-2,33  8 7,75 9,02 0,917 
Metabolic 
Body mass index           
Underweight 22 31 0,153 0,28 0,05-1,60  7 1,86 3,48 
0,123 
Normal 5 2 ----- ----- -----  53 7,36 11,64 
Overweight 11 27 0,221 1,74 0,72-4,24  38 6,53 6,32 
Obesity 4 13 0,189 2,30 0,66-8,02  17 11,12 14,54 
Type 2 Diabetes 
Mellitus 
6 22 0,062 2,59 0,95-7,02 
 
28 7,43 7,59 0,275 
Dyslipidemia 18 36 0,504 1,30 0,60-2,79  54 6,46 7,37 0,993 
Ostheoporosis 4 3 0,255 0,41 0,09-1,91  7 12,57 22,20 0,739 
Psychiatric 
Anxiety 15 26 0,992 1,00 0,45-2,20  41 7,24 11,57 0,991 
Depression 9 13 0,635 0,80 0,31-2,05  22 7,50 14,85 0,504 
Neoplasic 
Pulmonary 2 1 0,302 0,28 0,02-3,16  3 23,33 40,41 0,779 
Extra-pulmonary 3 7 0,655 1,38 0,34-5,64  10 8,90 7,37 0,236 
Other 
Chronic Kidney 
Disease 
4 11 0,399 1,69 0,50-5,67 
 
15 3,87 3,80 0,368 
Gastroesophageal 
reflux disease 
12 25 0,531 1,30 0,57-2,97 
 
37 8,46 12,06 0,603 
Gastritis 3 2 0,282 0,37 0,06-2,29  5 16,40 26,17 0,973 
Peptic Ulcer 1 0 NA NA NA  1 0 NA NA 
Chronic Hepatic 
Disease 
1 1 0,693 0,57 0,03-9,35 
 
2 6,50 9,19 0,966 
Benign Prostatate 
Hypertrophy 
7 6 0,176 0,45 0,14-1,43 
 
13 3,92 5,71 0,177 
¶ - logistic-regression analysis; OR – Odds Ratio; CI – Confidence Interval
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Table 5: Comparison of comorbidities between ED readmitted and non-readmitted patients for any cause and 
for AECOPD 
 ED Readmission 
 Any cause  AECOPD 
 No Yes  
Univariable 
analysis
¶
 
 
No Yes  
Univariable 
analysis
¶
 
 n=80 n=35 P-value OR 95% CI  n=92 n=23 P-value OR 95% CI 
Respiratory            
Community-acquired  
pneumonia in the last 12 
months 
16 61 0,720 0,83 0,29-2,33 
 
19 3 0,411 0,58 0,15-2,15 
Asthma 8 3 0,811 0,84 0,21-3,39  10 1 0,359 0,37 0,05-3,07 
Obstructive Sleep Apnea 6 4 0,494 1,60 0,42-6,03  7 3 0,414 1,82 0,43-7,67 
Bronchiectasis 20 11 0,476 1,38 0,57-3,30  26 5 0,530 0,71 0,24-2,10 
Cardiovascular            
Heart Failure 42 15 0,342 0,68 0,30-1,51  47 10 0,515 0,74 0,29-1,85 
Previous acute 
myocardial infarct 
8 0 NA NA NA 
 
8 0 NA NA NA 
Ischemic heart disease 18 4 0,173 0,44 0,14-1,43  19 3 0,411 0,58 0,15-2,15 
Arrhytmias 17 6 0,613 0,77 0,27-2,15  19 4 0,727 0,81 0,25-2,66 
Hypertension 54 20 0,288 0,64 0,28-1,45  61 23 0,383 0,66 0,26-1,68 
Peripheric artery disease 2 2 0,400 2,36 0,32-17,50  3 1 0,800 1,35 0,13-13,60 
Previous venous 
thrombosis/Pulmonary 
thromboembolism 
3 0 NA NA NA 
 
3 0 NA NA NA 
Previous stroke 4 4 0,225 2,45 0,58-10,43  5 3 0,214 2,61 0,58-11,83 
Metabolic            
Body mass index            
Underweight 37 16 0,170 3,08 0,62-15,39  41 12 0,258 2,56 0,50-13,07 
Normal 3 4 ----- ----- -----  4 3 ----- ----- ----- 
Overweight 27 11 0,898 0,94 0,37-2,35  31 7 0,626 0,77 0,27-2,19 
Obesity 13 4 0,595 0,71 0,20-2,52  16 1 0,154 0,21 0,03-1,78 
Type 2 Diabetes Mellitus  18 10 0,486 1,38 0,56-3,40  22 6 0,828 1,12 0,39-3,20 
Dyslipidemia 38 16 0,860 0,93 0,42-2,06  43 11 0,926 1,04 0,42-2,61 
Ostheoporosis 6 1 0,357 0,36 0,04-3,13  6 1 0,699 0,65 0,07-5,69 
Psychiatric            
Anxiety 31 10 0,296 0,63 0,27-1,50  36 5 0,126 0,43 0,15-1,27 
Depression 14 8 0,503 1,40 0,53-3,71  18 4 0,813 0,87 0,26-2,86 
Neoplasic            
Pulmonary 2 1 0,912 1,15 0,10-13,08  2 1 0,566 2,05 0,18-23,59 
Extra-pulmonary 9 1 0,174 0,23 0,03-1,91  9 1 0,421 0,42 0,05-3,49 
Other            
Chronic Kidney Disease 10 5 0,794 1,17 0,37-3,71  11 4 0,491 1,55 0,44-5,40 
Gastroesophageal 
reflux disease 
22 15 0,107 1,98 0,86-4,53 
 
25 12 0,025 2,92 1,14-7,47 
Gastritis 3 2 0,637 1,56 0,25-9,75  3 2 0,272 2,83 0,44-17,99 
Peptic Ulcer 1 0 NA NA NA  1 0 NA NA NA 
Chronic Hepatic Disease 2 0 NA NA NA  2 0 NA NA NA 
Benign Prostatate 
Hypertrophy 
11 2 0,225 0,38 0,08-1,81 
 
12 1 0,264 0,30 0,37-2,46 
¶ - logistic-regression analysis; AECOPD - acute exacerbation of chronic obstructive pulmonary disease; OR – Odds Ratio; 
CI – Confidence Interval; NA – Not applicable
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Table 6: Comparison of comorbidities between rehospitalized and non-rehospitalized patients for any cause 
and for AECOPD 
 Rehospitalization 
 Any cause AECOPD 
 No Yes  
Univariable 
analysis
¶
 
No Yes  
Univariable 
analysis
¶
 
 n=93 n=22 P-value OR 95% CI N=101 n=14 P-value OR 95% CI 
Respiratory           
Community-acquired 
pneumonia in the last 12 
months 
18 4 0,900 0,93 0,28-3,07 21 1 0,250 0,29 0,04-2,37 
Asthma 9 2 0,933 0,93 0,19-4,66 11 0 NA NA NA 
Obstructive Sleep Apnea 8 2 0,942 1,06 0,21-5,40 8 2 0,435 1,94 0,37-10,21 
Bronchiectasis 24 7 0,569 1,34 0,49-3,68 27 4 0,885 1,10 0,32-3,80 
Cardiovascular           
Heart Failure 47 10 0,668 0,82 0,32-2,07 51 6 0,593 0,74 0,24-2,27 
Previous acute 
myocardial infarct 
8 0 NA NA NA 8 0 NA NA NA 
Ischemic heart disease 19 3 0,470 0,61 0,16-2,30 19 3 0,816 1,18 0,30-4,64 
Arrhytmias 18 5 0,722 1,23 0,40-3,76 20 3 0,887 1,11 0,28-4,33 
Hypertension 62 12 0,289 0,6 0,23-1,54 65 9 0,996 1,00 0,31-3,20 
Peripheric artery disease 3 1 0,762 1,43 0,14-14,42 3 1 0,439 2,51 0,24-25,98 
Previous venous 
thrombosis/Pulmonary 
thromboembolism 
3 0 NA NA NA 3 0 NA NA NA 
Previous stroke 5 3 0,186 2,78 0,61-12,64 5 3 0,038 5,24 1,10-24,95 
Metabolic           
Body mass index           
Underweight 42 11 0,639 1,53 0,26-8,96 46 7 0,299 2,63 0,42-16,26 
Normal 5 2 ----- ----- ----- 5 2 ----- ----- ----- 
Overweight 30 8 0,972 1,02 0,37-2,84 33 5 0,994 1,00 0,29-3,41 
Obesity 16 1 0,187 0,24 0,03-2,00 17 0 NA NA NA 
Type 2 Diabetes Mellitus  21 7 0,367 1,60 0,58-4,44 23 5 0,296 1,88 0,57-6,18 
Dyslipidemia 45 9 0,528 0,74 0,29-1,89 46 8 0,418 1,59 0,52-4,93 
Ostheoporosis 6 1 0,738 0,69 0,08-6,05 6 1 0,860 1,22 0,14-10,94 
Psychiatric           
Anxiety 33 8 0,938 1,04 0,40-2,73 37 4 0,557 0,69 0,20-2,36 
Depression 17 5 0,634 1,31 0,43-4,06 19 3 0,816 1,18 0,30-4,64 
Neoplasic           
Pulmonary 2 1 0,536 2,17 0,19-25,03 2 1 0,289 3,81 0,32-44,98 
Extra-pulmonary 9 1 0,454 0,44 0,05-3,70 9 1 0,826 0,79 0,09-6,72 
Other           
Chronic Kidney Disease 10 5 0,143 2,44 0,74-8,05 11 4 0,078 3,27 0,88-12,22 
Gastroesophageal reflux 
disease 
27 10 0,143 2,04 0,79-5,27 29 8 0,040 3,31 1,06-10,38 
Gastritis 3 2 0,245 3,00 0,47-19,15 3 2 0,078 5,44 0,83-35.93 
Peptic Ulcer 1 0 NA NA NA 1 0 NA NA NA 
Chronic Hepatic Disease 2 0 NA NA NA 2 0 NA NA NA 
Benign Prostatate 
Hypertrophy 
11 2 0,716 0,75 0,15-3,63 12 1 0,604 0,57 0,07-4,76 
¶ - logistic-regression analysis; AECOPD - acute exacerbation of chronic obstructive pulmonary disease; OR – Odds Ratio; 
CI – Confidence Interval ; NA – Not applicable 
 
  
 Comorbidities and COPD Assessment Test (CAT) responsiveness in Acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD) 
 
30 
Table 7: Comparison of comorbidities and fatal outcome 
 Fatal outcome  
 No Yes P-value 
 n=111 n=4  
Respiratory    
Community-acquired pneumonia in the last 12 months 22 0 NA 
Asthma 11 0 NA 
Obstructive Sleep Apnea 10 0 NA 
Bronchiectasis 31 0 NA 
Cardiovascular    
Heart Failure 55 2 0,684 
Previous acute myocardial infarct 7 1 0,254 
Ischemic heart disease 21 1 0,578 
Arrhytmias 22 1 0,596 
Hypertension 71 3 0,551 
Peripheric artery disease 4 0 NA 
Previous venous thrombosis/Pulmonary 
thromboembolism 
3 0 NA 
Previous stroke 6 2 0,024 
Metabolic    
Body mass index    
   Underweight 6 1 
0,253 
   Normal 52 1 
   Overweight 36 2 
   Obesity 17 0 
Type 2 Diabetes Mellitus  28 0 NA 
Dyslipidemia 52 2 0,643 
Ostheoporosis 7 0 NA 
Psychiatric    
Anxiety 40 1 0,551 
Depression 20 2 0,165 
Neoplasic    
Pulmonary 2 1 0,102 
Extra-pulmonary 9 1 0,309 
Other    
Chronic Kidney Disease 15 0 NA 
Gastroesophageal reflux disease 35 2 0,593 
Gastritis 5 0 NA 
Peptic Ulcer 1 0 NA 
Chronic Hepatic Disease 2 0 NA 
Benign Prostatate Hypertrophy 13 0 NA 
NA – Not applicable    
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Discussion  
In this study, the relevance of comorbidities in patients admitted for AECOPD is 
emphasized. Cardiovascular, metabolic and psychiatric diseases along with GERD are very 
prevalent conditions and show the importance in the course of COPD. Hypertension (64,4%) is 
a major diagnosis among COPD patients, accounting for a reported prevalence of  40-60% 
throughout the literature [23] [24].  Ischemic heart disease (19,1%) and an history of myocardial 
infarction (MI) (7%) have higher prevalence than in other studies. In these, the prevalence of 
ischemic heart disease was reported to be 9% [25], angina 6,6% and acute MI 2,3% [24]. The 
same trend was found in a Portuguese study, where a prevalence of 18% was reported [26]. 
This may represent a singularity of the Portuguese COPD population.  
Hypertension and ischemic heart disease are the most common causes of heart failure. 
Heart failure is more prevalent than in other studies [27] [28]. A prevalence of 7% [25] to 25% in 
patients with COPD aged ≥65 years [28] was described. However, due to overlapping signs and 
symptoms, 80% of heart failure cases in COPD elderly patients are unrecognized [28]. 
The prevalence of arrhythmias is also higher than reported (20% vs 12-14%) [29] [30]. The 
same Portuguese study also showed a higher prevalence (18%), which may also represent a 
singularity of the Portuguese population. The majority of the arrhythmias are AF [2]. 
Metabolic comorbidities are also relevant. Dyslipidemia (47% vs 9-51% [31] [2]) and type 
2 diabetes mellitus (24,4% vs 11-25% [32] [33]) prevalences are consistent with published data. 
Obesity (14,8% vs 18%-24,6% [34] [35]) and underweight are less prevalent compared to other 
studies (6,1% vs 11.7% [36]). The same trend was found for ostheoporosis (6,1% vs 23%) [37] 
which may be related to underdiagnosis. The prevalence of chronic kidney disease (CKD) is 
lower than the 22% reported [38]. 
The risk of cardiovascular disease is increased in COPD patients due to several 
reasons. Smoking is a leading risk factor for both COPD and ischemic heart disease [39]. 
Moreover, FEV1 is a significant risk factor for cardiovascular morbidity and mortality, 
independent of smoking [40]. Individuals with reduced FEV1 are at increased risk of 
atherosclerosis [41]. COPD patients show accelerated degradation of elastin and increased 
deposition of collagen leading to increased arterial stiffness. This could play a role in the 
pathogenesis of hypertension [42]. Arrhythmias, especially AF, often reflect the presence of 
ischemic heart disease and/or hypertension and are more common as airflow limitation worsens 
[43]. 
Metabolic comorbidities are related to cardiovascular disease as they represent 
additional risk factors. Type 2 diabetes mellitus, dyslipidemia and obesity share common 
mechanisms in COPD, namely central obesity, reduced physical activity, increase smoking, 
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corticosteroids use and disease-related inflammation and oxidative stress [44]. BMI and 
diabetes are significantly associated with CKD [45]. 
Anxiety and depression are important comorbidities that often coexist [46]. The reported 
prevalences for both diseases are wide, ranging from 7% to 80%  for depression [47] [48] and 
from 6% to 74% for anxiety [48]. This is probably due to heterogeneity in diagnostic criteria. The 
risk factors for anxiety or depression in COPD patients include severe dyspnea, poor health-
related quality of life, impairment of physical functioning, long-term oxygen therapy, acute 
exacerbations, limited airflow reversibility, living alone, unsupportive families, low BMI and 
medical comorbidities [49]. 
  GERD reported prevalence ranges between 30-60% in COPD patients [50]. Several 
mechanisms link GERD to COPD. Firstly, symptoms of GERD are more common with increased 
intra-abdominal pressure, such as coughing, obesity [51] and hyperinflation of the lungs where 
the diaphragm is displaced caudally [52]. Secondly, acidification of the lower esophagus 
increases cough responsiveness in patients with chronic cough [53], and worsens airway 
hyperreactivity [54]. Thirdly, the autonomic dysfunction often found in COPD patients can lead 
to impaired lower esophageal sphincter tone and delayed gastric emptying [55]. Moreover, 
salbutamol at higher dose reduce LOS tone [56].  
Theoretically, the risk of cerebrovascular events and the prevalence of peripheral arterial 
disease (PAD) are increased in COPD patients due to the same reasons mentioned above for 
cardiovascular diseases. However, previous history of stroke (7%) has a lower prevalence than 
reported: 7% vs 9,9% [57] for stroke and 14 % [50] for any cerebrovascular event in COPD. The 
prevalence of cerebrovascular accidents in Portugal varies from 8-2,1% [58] [59]. For this 
reason, this data is difficult to interpret.  The prevalence of PAD in Portugal is 5,9% [60]which is 
higher than the prevalence found. These differences may be related to the specific population of 
the present studyand to underdiagnosis. 
The prevalences for asthma (9,6%) and obstructive sleep apnea (OSA) (8,7%) are not 
consistent with the published data. Reported prevalence of asthma among elderly patients with 
COPD can be as high as 40% [2]. The prevalence of OSA in COPD is not higher than in the 
general population (around 5%) [2]. The increased risk of neoplastic disorders among COPD 
patients is believed to be due to a common major risk factor: smoking  [61]. Of the 10 patients 
found to have an extrapulmonary neoplasm, 8 had a smoking-related cancer, namely colorectal 
cancer, bladder cancer and laryngeal cancer. 
The majority of the AECOPD patients that present to ED are hospitalized and mean 
length of hospitalization (11,5) is higher than expected. The mean of days of hospitalization was 
8,2 and 7,0 in 2006 and 2010 respectively [62]. This may be due to an increased rate of 
complications during the hospitalization inherent to disease or comorbidities severity. 
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Compared to other studies, the ED readmission rate for any cause and for AECOPD is 
higher. In a study, a readmission rate of 9,2% at 30 days and 20,3% at 90 days following an 
admission for AECOPD was reported. In a north-american analysis of 2008, the 30-day all-
cause rehospitalization rate after a COPD admission was 20,5%, with 7,1% readmitted primarily 
for COPD [17]. A follow-up analysis of the same database for 2010 found a similar 30-day 
readmission rate of 20.9% [18] [63]. This disparity may be related to differences concerning 
patient characteristics, namely comorbidities and their severity and insufficient disease control 
as well as other factors related to supportive care after hospital discharge.  
In another study, three months after an admission for AECOPD, 20,2% of the patients 
were readmitted for COPD, 22% for heart failure, 18% for infection and 10% for ischemic heart 
disease. [64]. This study shows similar causes for readmission, in the same order of 
prevalence: AECOPD, heart failure and infection 
The high rate of readmissions for heart failure supports the fact that heart failure and 
COPD have common pathways that cause mutual disease progression apart from the systemic 
effects of smoking and inflammation, such as the renin-angiotensin system overactivation which 
negatively affects systemic and pulmonary circulation through vasoconstriction; the sympathic 
system overactivity, which is harmful for the cardiovascular system, can be increased in more 
severe COPD; and, at a late stage, both diseases share the same type of metabolic modulation, 
increasing the lipid metabolism, resulting in cachexia [65]. The data supports the fact that an 
AECOPD may be able to induce a heart failure decompensation, which demonstrates the close 
interaction between both entities. Despite the higher rate of readmissions compared to other 
studies, none of the patients died during the index ED admission, which contrasts with other 
studies that reported a mortality of 7,4% [66] and of 8,5 at 30 days [67].  
Other studies reported that CAT is statically different in AECOPD and in the stable state 
[21] [16] [68].  CAT shows responsiveness to AECOPD treatment. The CAT score during the 
ED admission is similar to other studies, ranging from 21,4±7,7 [14] to 22,8±4,9 [17].  CAT score 
at 30 days after hospital discharge (18,4±6,8 ) is also comparable to a study that uses the same 
period of follow-up (19,9±7,7) [14]. Two other studies, in which the follow-up period was 6 
weeks and 12 weeks, showed a CAT score after follow-up respectively of 15,6±4,5 (CAT score 
pre-AECOPD treatment 22,8±4,9) [17] and 12,1±5,9 (CAT score pre-AECOPD treatment 
22,0±7,0) [18]. CAT recovery (3,6±3,7) is significantly different from the one reported in a study 
with the same follow-up period (1,4±5,3, p=0,03) [14]. However, it varies significantly and in a 
non-proportional manner according to the follow-up periods: at 12 weeks the CAT recovery was 
6,5±3,9 (p=0,001) in one study [17] and at 6 weeks 9,9±5,1 (p=0,001) in another [18].  
Hospitalized patients have a slightly better CAT recovery. This is probably due to the 
better clinical monitoring and care, not only for the AECOPD but also for comorbidities. It may 
also represent an increase in self-confidence among patients who were more closely monitored. 
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ED readmitted and rehospitalized patients for any cause and for AECOPD have a worse CAT 
recovery compared to non-readmitted or rehospitalized patients. This suggests that CAT is able 
to detect disturbances in the clinical state of the patient related not only to COPD but also to 
other clinical entities that negatively affect AECOPD recovery.  
A study reported a difference in CAT related with BMI [69]. In the present study no 
association between CAT during ED admission and BMI is found; however, BMI is associated 
with CAT recovery. Underweight patients show the worst CAT recovery, probably due to the fact 
that this group of patients have a more severe disease and less responsive to treatment. Low 
BMI was previously associated with poor prognosis in stable and exacerbated COPD patients  
[70]. Obese patients also show worse CAT recovery compared to other groups that may be 
related to associated cardiovascular and metabolic comorbidities. However, overweight patients 
recover better than the normal BMI patients. This fact is likely the result of the protective role of 
the excess weight. This phenomenon, known as “obesity paradox”, is not unique in COPD - and 
in this case may be called the “overweight paradox”. A possible explanation is that obesity (or 
overweight, in this case) may be a protective factor in advanced COPD patients, when loss of 
fat-free mass is an important short-term risk factor for poor outcomes; on the other hand, in 
earlier stages of COPD, obesity-related conditions such as inflammation and metabolic 
syndrome are harmful long-term effects [70]. A study showed significant difference on the CAT 
score recovery at 6 weeks between patients with depressive symptoms (7,0, p=0,012) and 
those without (11,0, p=0,012) [19]. This is not found in this study. 
CAT during ED admission and CAT recovery are independent of the number of 
comorbidities. The same result was reported in other studies, where the comorbidity burden 
was classified according to the presence of 0, 1-2 or>=3 diseases [68] [69]. 
The association of GERD and ED readmission rate for AECOPD at 30 days underlines 
the relevance of this comorbidity in the course of COPD. Several studies reported the 
association between GERD symptoms and frequency of AECOPD [71] [72] [73]. In this study, 
this association may reflect the negative influence of GERD on AECOPD recovery by increasing 
the risk of therapeutic ineffectiveness. This is supported by the fact that GERD is not associated 
with ED readmissions for all causes, but only with ED readmission due to AECOPD. Moreover, 
GERD is also associated with rehospitalizations for AECOPD. This may reflect the severity of 
the AECOPD relapses in patients with this comorbidity. However, GERD is not associated with 
hospitalization or with the length of hospitalization during the first ED admission.  
Despite the relevance of cerebrovascular disease, there is limited data on impact on 
COPD  [2]. Previous history of stroke is associated with rehospitalization for AECOPD at 30 
days. Patients with past history of stroke are likely to have dysphagia, increasing the risk of 
aspiration, pneumonia and disability. [74]. COPD patients with past history of stroke had higher 
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risk of aspiration than stroke patients without COPD [75]. This increased risk of aspiration may 
be responsible for the increased risk of rehospitalization for AECOPD. 
A study evaluated hospital mortality, length of hospital stay, 90 days readmission rate 
and mortality after an admission for AECOPD. The burden of comorbidities was associated with 
worse outcomes for all four measures. In-hospital mortality risk was increased with cor 
pulmonale, left ventricular failure, neurological conditions and non-respiratory malignancies 
whilst 90 day death was also increased in patients with lung cancer or arrhythmias. Ischemic 
and other heart diseases were important factors in the readmission rate [76]. In this study, 
specific comorbidities are not associated with hospitalization at ED admission or with the length 
of hospitalization. Furthermore, heart diseases are not associated with readmissions. On the 
other hand, the association between 30-day fatality and previous history of stroke may reflect 
the importance of neurological diseases. The lack of association between specific comorbidities 
and fatality may be due to the low fatality rate. There is also a lack of association between the 
number of comorbidities and length of hospitalization, ED readmission or rehospitalizations . 
This result may reflect the influence of other factors such as COPD severity, comorbidities, 
treatments performed before the ED admission, ED treatment strategies for AECOPD and 
complications during the hospitalization. It is also possible that the sample was too small to find 
other relationships. Finally, a small variability and the finding of clusters of comorbidities 
compromise the statistical analysis.  
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Conclusion 
This study confirms the high prevalence of comorbidities in ED admitted patients for 
AECOPD. AECOPD is associated with a high rate of hospitalization and length of 
hospitalization, and a high rate of ED readmissions and rehospitalizations at 30 days. The 
analysis of readmission causes also shows the interaction between COPD and other important 
comorbidity: heart failure. The presence of GERD and/or past history of stroke modify ED 
readmission and rehospitalization rates; this, may be through the same pathophysiological 
mechanism – the aspiration of particles. The presence of cerebrovascular diseases worsens 30-
day fatality.  CAT shows to be an excellent tool to evaluate AECOPD recovery as it is 
responsive to improvement and sensitive for AECOPD relapses and other clinical entities that 
affect patient recovery.  BMI showed to be relevant concerning CAT recovery.  
The severity of COPD and comorbidities, the therapies performed before the ED 
admission, ED treatment strategies for AECOPD and comorbidities, and complications that 
intervene during the hospitalization may play a role that needs to be taken into account. 
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